Clinical Trial Update: Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia [Phase 1]

View source ↗

Summary

A Phase 1 trial of recombinant human Mannose-Binding Lectin (MBL) in young patients with MBL deficiency and fever with neutropenia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infection
• Leukemia
• Lymphoma
• Myelodysplastic Syndromes
• Neutropenia

Drugs mentioned

• Recombinant Human Mannose-Binding Lectin (MBL) (mannose-binding lectin)

Snippet

Sponsor: Enzon Pharmaceuticals, Inc. | Conditions: Fever, Sweats, and Hot Flashes, Infection | Phase 1 | Status: WITHDRAWN